Compare Novo Nordisk A/S (NVO) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Workiva Inc — how do they compare? Novo Nordisk A/S trades at $38.63 (market cap $165.31B), while Workiva Inc trades at $73.07 (market cap $4.01B). The key difference: Novo Nordisk A/S is far larger — about 41.2× Workiva Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Workiva Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Workiva Inc for 21 Days on average.
| NVO | WK | |
|---|---|---|
Market Cap | $165.31B | $4.01B |
Volume | 11,432,838 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $63.98 | $93.31 |
52-Week Low | $35.29 | $44.31 |
Typical Hold Time | 116 Days | 21 Days |
Enterprise Value | $179.56B | $3.99B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Workiva (WK) trades at $73.20, up 2.33% with bullish technical indicators and strong analyst support. The company shows improving fundamentals with revenue growth from $885M to $966M and a shift from a $26M loss to $47M profit in 2026. Recent product innovations in AI and regulatory platforms highlight business momentum, supported by consistent earnings beats in recent quarters.
Outlook remains positive with 89% analyst buy ratings and $86 consensus target offering 17% upside. Key risks include high valuation multiples (P/E 87.7) and competitive pressures in regulatory technology. The stock's technical strength and fundamental improvement suggest continued growth potential, though investors should monitor execution on profitability targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
